- Criminal Judge Asks Cotchett, Pitre & McCarthy to Weigh in on PG&E's Safety Record
- Defrauded Investors May Lose Their Right to Recovery: Trump Administration Pushes for Regulatory Changes that Would Allow Companies to Avoid Securities Class Actions Through the Use of Mandatory Arbitration Agreements
- Finra Enacts Important Rule to Protect Seniors Against Fraudulent Activity
- The CPFB Remains Under Attack: Consumers Should Care About an Agency that has Recovered More than $11.9 Billion for Everyday Workers
- Supreme Court Upholds Right to Bring Securities Act Class Actions in State Court
- Cracking Down on the “Rehab Riviera”
- Protecting Our Seniors—Stating a Cause of Action for Elder Abuse is Not as Difficult as Defendants Often Claim
- “Smart” toys raise privacy and safety concerns for kids
- Strict new privacy and data protections soon take effect in European countries
- Is your cell phone tracking every move you make?
Showing 4 posts in Antitrust.
On April 14, 2017, the United States Court of Appeals for the Ninth Circuit affirmed the district court’s partial denial of All Nippon Airways, EVA Airways, and China Airlines’ motions for summary judgment, holding that the filed rate doctrine does not bar an antitrust class action challenging the airlines’ unfiled fares, fuel surcharges, and special discount fares. This marked the first time the Ninth Circuit addressed the application of the filed rate doctrine to airfares and fees. Read More ›
Federal and state prosecutors are bearing down on pharmaceutical giants, and the glare on the lucrative generic drug industry is showing no signs of waning: last week, the Attorney General of Alabama announced it joined 39 other states suing many of the largest pharmaceutical corporations in the world for unlawfully skyrocketing the prices of common, household prescription medication to unprecedented levels. Read More ›
Legal scholars have been forecasting that generic drugs will be the next big antitrust price-fixing case, and 2017 seems to be confirming this prediction thus far. In December 2016, the Antitrust Division of the United States Department of Justice (“DOJ”) charged two former executives of Heritage Pharmaceuticals Inc. with price-fixing, bid rigging, and customer allocation of two generic drugs. Shortly thereafter, 20 states filed civil lawsuits against Heritage and its competitors—Mylan NV, Teva Pharmaceuticals, Mayne Pharma Group Ltd., Heritage Pharmaceuticals Inc., Aurobindo Pharma Ltd., and Citron Pharma LLC—for allegedly conspiring to fix the prices of two generic drugs. The two drugs at issue are the delayed-release version of the antibiotic doxycycline hyclate and the diabetes drug glyburide. A total of 40 states have now filed suits. Read More ›
On December 21, 2015, Judge Ronald M. Whyte of the Federal Court for the Northern District of California appointed Cotchett, Pitre & McCarthy, LLP. (“CPM”) lead counsel for the indirect purchasers in a class action alleging that a number of companies illegally conspired to inflate the prices consumers and businesses paid for resistors. Read More ›